Cover Image
市場調查報告書

細菌性結膜炎治療藥的全球市場:2016∼2020年

Global Bacterial Conjunctivitis Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 353151
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
細菌性結膜炎治療藥的全球市場:2016∼2020年 Global Bacterial Conjunctivitis Drugs Market 2016-2020
出版日期: 2016年02月17日 內容資訊: 英文 57 Pages
簡介

細菌性結膜炎,是感染結膜的感染力非常強的眼部疾病,葡萄球菌、溶血鏈球菌、披衣菌感染等是原因物質。全球細菌性結膜炎治療藥市場,預計2016∼2020年以年複合成長率2.77%擴大。

本報告提供全球細菌性結膜炎治療藥市場現狀與今後的成長預測,各地區趨勢,以及市場趨勢與課題,主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 概要:細菌性結膜炎

  • 結膜炎
  • 細菌性結膜炎
  • 症狀
  • 診斷
  • 管理
  • 經濟負擔

第6章 開發平台分析

第7章 抗微生物體制

  • 改善抗生劑的技術創新的配合措施

第8章 美國的抗生劑使用相關法規

第9章 市場情況

  • 市場概要
  • 市場規模與預測
  • 美國的細菌性結膜炎治療藥市場
  • 波特的五力分析

第10章 各類藥物市場區隔

第11章 各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第12章 推動市場的要素

第13章 促進要素的影響

第14章 市場課題

第15章 促進要素及課題的影響

第16章 市場趨勢

第17章 供應商環境

  • 競爭模式
  • Akorn
  • Alcon
  • Allergan
  • Bausch & Lomb
  • 其他值得注意的供應商

第18章 附錄

第20章 關於Technavio

圖表

目錄
Product Code: IRTNTR8368

About Bacterial Conjunctivitis Drugs

Bacterial conjunctivitis, which affects either one or both the eyes, is an extremely contagious eye condition wherein the conjunctiva is infected. Staphylococci, streptococci, gonococci, and Chlamydia are some of the causative agents of bacterial conjunctivitis. Extremely pathogenic bacteria such as Chlamydia trachomatis and Neisseria gonorrhea cause severe bacterial conjunctivitis. Antibiotics help in eradicating the microbes, resulting in faster clearance of the symptoms. Broad-spectrum antibiotics such as Besivance, Zymaxid, Maxitrol, and AzaSite, in the form of antibiotic pills, ointment, or eye drops help treat the infection. Fluoroquinolones, macrolides, aminoglycosides, and phenicols are among the different classes of antibiotics that are commonly prescribed to treat the condition.

Technavio's analysts forecast the global bacterial conjunctivitis drugs market to grow at a CAGR of 2.77% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global bacterial conjunctivitis drugs market for 2015-2020. To calculate the market size, it considers revenue generated from the sales of branded and generic drugs along with over-the-counter (OTC) drugs used to treat bacterial conjunctivitis.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Bacterial Conjunctivitis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Akorn
  • Alcon
  • Allergan
  • Bausch & Lomb

Other Prominent Vendors

  • Bayer
  • Daiichi Sankyo
  • F. Hoffmann-La Roche
  • InSite Vision
  • Merck
  • Nicox
  • Novartis
  • Perrigo
  • Pfizer
  • Santen Pharmaceutical
  • Shire
  • Valeant Pharmaceuticals

Market driver

  • Rising awareness about infections
  • For a full, detailed list, view our report

Market challenge

  • Patent expiry of drugs
  • For a full, detailed list, view our report

Market trend

  • Patient assistance programs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Overview: Bacterial conjunctivitis

  • Conjunctivitis
  • Bacterial conjunctivitis
  • Signs and symptoms
  • Diagnosis
  • Management
  • Economic burden

PART 06: Pipeline analysis

  • FST-100
  • AzaSite Xtra (ISV-405)

PART 07: Antimicrobial resistance

  • Initiatives to improve innovation of antibiotics

PART 08: Legislation relating to antibiotic use in US

PART 09: Market landscape

  • Market overview
  • Market size and forecast
  • Bacterial conjunctivitis drugs market in US
  • Five forces analysis

PART 10: Market segmentation by drug class

  • Fluoroquinolones
  • Aminoglycosides
  • Macrolides
  • Other

PART 11: Geographical segmentation

  • Global bacterial conjunctivitis drugs market by geography 2015-2020
  • Bacterial conjunctivitis drugs market in Americas
  • Bacterial conjunctivitis drugs market in EMEA
  • Bacterial conjunctivitis drugs market in APAC

PART 12: Market drivers

  • Rising awareness about infection
  • Development of multidrug-resistant variants
  • Prevalence of bacterial conjunctivitis

PART 13: Impact of drivers

PART 14: Market challenges

  • Patent expiry of drugs
  • Contentment with existing therapies
  • Adverse effects and limited efficacy of drugs
  • Weak R&D of drugs

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Strategic alliances and M&A
  • Use of combination therapies
  • Patient assistance programs

PART 17: Vendor landscape

  • Competitive scenario
  • Akorn
  • Alcon
  • Allergan
  • Bausch & Lomb
  • Other prominent vendors

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Types of conjunctivitis
  • Exhibit 03: Types of bacterial conjunctivitis
  • Exhibit 04: Signs and symptoms of bacterial conjunctivitis
  • Exhibit 05: Drugs used to treat conjunctivitis
  • Exhibit 06: Global bacterial conjunctivitis drugs market: Pipeline portfolio
  • Exhibit 07: Causes of antimicrobial resistance
  • Exhibit 08: Initiatives improving antibiotic innovation
  • Exhibit 09: Legislation relating to antibiotic use in US
  • Exhibit 10: Global bacterial conjunctivitis drugs market 2015-2020 ($ billions)
  • Exhibit 11: Snapshot of global bacterial conjunctivitis drugs market
  • Exhibit 12: Percentage share of bacterial conjunctivitis drugs market in US
  • Exhibit 13: Bacterial conjunctivitis drugs market in US 2015-2020 ($ millions)
  • Exhibit 14: Five forces analysis
  • Exhibit 15: Global bacterial conjunctivitis drugs market by drug class
  • Exhibit 16: Global bacterial conjunctivitis drugs market by geography 2015
  • Exhibit 17: Global bacterial conjunctivitis drugs market by geography 2015-2020 ($ billions)
  • Exhibit 18: Bacterial conjunctivitis drugs market in Americas 2015-2020 ($ millions)
  • Exhibit 19: Bacterial conjunctivitis drugs market in EMEA 2015-2020 ($ millions)
  • Exhibit 20: Bacterial conjunctivitis drugs market in APAC 2015-2020 ($ millions)
  • Exhibit 21: Global bacterial conjunctivitis drugs market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 22: Key drivers
  • Exhibit 23: Impact of drivers
  • Exhibit 24: Key challenges
  • Exhibit 25: Impact of drivers and challenges
  • Exhibit 26: Key trends
  • Exhibit 27: Akorn: YoY growth and revenues in ophthalmic segment 2011-2013 ($ millions)
  • Exhibit 28: Akorn: Key takeaways
  • Exhibit 29: Business segmentation by revenue 2014
  • Exhibit 30: Alcon: YoY growth and revenue generated from sales of ophthalmic products 2011-2014 ($ billions)
  • Exhibit 31: Alcon: Key takeaways
  • Exhibit 32: Allergan: Key takeaways
  • Exhibit 33: Bausch & Lomb: Key takeaways
Back to Top